|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk factors associated with the development of ischemic colitis显示文摘AIM:To ascertain the role of cardiovascular risk factors,cardiovascular diseases,standard treatments and other diseases in the development of ischemic colitis(IC).METHODS:A retrospective,case-control study was designed,using matched data and covering 161 incident cases of IC who required admission to our hospital from 1998 through 2003.IC was diagnosed on the basis of endoscopic findings and diagnostic or compatible his-tology.Controls were randomly chosen from a cohort of patients who were admitted in the same period and required a colonoscopy,excluding those with diagnosis of colitis.Cases were matched with controls(ratio 1:2),by age and sex.A conditional logistic regression was performed.RESULTS:A total of 483 patients(161 cases,322 con-trols)were included;mean age 75.67±10.03 years,55.9%women.The principal indications for colonos-copy in the control group were lower gastrointestinal hemorrhage(35.4%),anemia(33.9%),abdominal pain(19.9%)and diarrhea(9.6%).The endoscopic findings in this group were hemorrhoids(25.5%),diverticular disease(30.4%),polyps(19.9%)and colorectal cancer(10.2%).The following variables were associated with IC in the univariate analysis:arterial hypertension(P= 0.033);dyslipidemia(P<0.001);diabetes mellitus(P =0.025);peripheral arterial disease(P=0.004);heart failure(P=0.026);treatment with hypotensive drugs(P=0.023);angiotensin-converting enzyme inhibitors;(P=0.018);calcium channel antagonists(P=0.028);and acetylsalicylic acid(ASA)(P<0.001).Finally,the following variables were independently associated with the development of IC:diabetes mellitus[odds ratio(OR)1.76,95%confidence interval(CI):1.001-3.077,P=0.046];dyslipidemia(OR 2.12,95%CI:1.26-3.57,P=0.004);heart failure(OR 3.17,95%CI:1.31-7.68,P=0.01);peripheral arterial disease(OR 4.1,95%CI:1.32-12.72,P=0.015);treatment with digoxin(digitalis)(OR 0.27,95%CI:0.084-0.857,P=0.026);and ASA(OR 1.97,95%CI:1.16-3.36,P=0.012).CONCLUSION:The development of an episode of IC was independently associated with diabetes,dyslipid-emia,presence of heart failure,peripheral arterial dis-ease and treatment with digoxin or ASA. | Joaquín Cubiella Fernández Luisa Núez Calvo Elvira González Vázquez Maria Jesús García García Maria Teresa Alves Pérez Isabel Martínez Silva Javier Fernández Seara | 2010 | World Journal of Gastroenterology2010，16，36： | 27 |
| 2 | Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis显示文摘Hepatitis B virus (HBV) is a very common infection worldwide. Its reactivation in patients receiving immunosuppression has been widely described as being associated with significant morbidity and mortality unless anti-viral prophylaxis is administered. Treatment in inflammatory bowel disease (IBD) patients has changed in recent years and immunosuppression and biological therapies are now used more frequently than before. Although current studies have reported an incidence of hepatitis B in inflammatory bowel disease patients similar to that in the general population, associated liver damage remains an important concern in this setting. Liver dysfunction may manifest in several ways, from a subtle change in serum aminotransferase levels to fulminant liver failure and death. Patients undergoing double immunosuppression are at a higher risk, and reactivation usually occurs after more than one year of treatment. As preventive measures, all IBD patients should be screened for HBV markers at diagnosis and those who are positive for the hepatitis B surface antigen should receive antiviral prophylaxis before undergoing immunosuppression in order to avoid HBV reactivation. Tenofovir/entecavir are preferred to lamivudine as nucleos(t)ide analogues due to their better resistance profile. In patients with occult or resolved HBV, viral reactivation does not appear to be a relevant issue and regular DNA determination is recommended during immunosuppression therapy. Consensus guidelines on this topic have been published in recent years. The prevention and management of HBV infection in IBD patients is addressed in this review in order to address practical | Pilar López-Serrano Jose Lázaro Pérez-Calle Maria Dolores Sánchez-Tembleque | 2013 | World Journal of Gastroenterology2013，19，9： | 12 |
| 3 | Helicobacter pylori and autoimmune disease:Cause or bystander显示文摘Helicobacter pylori(H.pylori)is the main cause of chronic gastritis and a major risk factor for gastric cancer.This pathogen has also been considered a potential trigger of gastric autoimmunity,and in particular of autoimmune gastritis.However,a considerable number of reports have attempted to link H.pylori infection with the development of extra-gastrointestinal autoimmune disorders,affecting organs not immediately relevant to the stomach.This review discusses the current evidence in support or against the role of H.pylori as a potential trigger of autoimmune rheumatic and skin diseases,as well as organ specific autoimmune diseases.We discuss epidemiological,serological,immunological and experimental evidence associating this pathogen with autoimmune diseases.Although over one hundred autoimmune diseases have been investigated in relation to H.pylori,we discuss a select number of papers with a larger literature base,and include Sj grens syndrome,rheumatoid arthritis,systemic lupus erythematosus,vasculitides,autoimmune skin conditions,idiopathic thrombocytopenic purpura,autoimmune thyroid disease,multiple sclerosis,neuromyelitis optica and autoimmune liver diseases.Specific mention is given to those studies reporting an association of anti-H.pylori antibodies with the presence of autoimmune disease-specific clinical parameters,as well as those failing to find such associations.We also provide helpful hints for future research. | Daniel S Smyk Andreas L Koutsoumpas Maria G Myt-ilinaiou Eirini I Rigopoulou Lazaros I Sakkas Dimitrios P Bogdanos | 2014 | World Journal of Gastroenterology2014，20，3： | 12 |
| 4 | Metabolic and hepatic effects of liraglutide,obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis显示文摘AIM To evaluate the pharmacodynamics of compounds in clinical development for nonalcoholic steatohepatitis(NASH) in obese mouse models of biopsy-confirmedNASH.METHODS Male wild-type C57 BL/6 J mice(DIO-NASH) and Lep^(ob/ob)(ob/ob-NASH) mice were fed a diet high in trans-fat(40%), fructose(20%) and cholesterol(2%) for 30 and 21 wk, respectively. Prior to treatment, all mice underwent liver biopsy for confirmation and stratification of liver steatosis and fibrosis, using the nonalcoholic fatty liver disease activity score(NAS) and fibrosis staging system. The mice were kept on the diet and received vehicle, liraglutide(0.2 mg/kg, SC, BID), obeticholic acid(OCA, 30 mg/kg PO, QD), or elafibranor(30 mg/kg PO, QD) for eight weeks. Within-subject comparisons were performed on changes in steatosis, inflammation, ballooning degeneration, and fibrosis scores. In addition, compound effects were evaluated by quantitative liver histology, including percent fractional area of liver fat, galectin-3, and collagen 1 a1.RESULTS Liraglutide and elafibranor, but not OCA, reduced body weight in both models. Liraglutide improved steatosis scores in DIO-NASH mice only. Elafibranor and OCA reduced histopathological scores of hepatic steatosis and inflammation in both models, but only elafibranor reduced fibrosis severity. Liraglutide and OCA reduced total liver fat, collagen 1 a1, and galectin-3 content, driven by significant reductions in liver weight. The individual drug effects on NASH histological endpoints were supported by global gene expression(RNA sequencing) and liver lipid biochemistry.CONCLUSION DIO-NASH and ob/ob-NASH mouse models show distinct treatment effects of liraglutide, OCA, and elafibranor, being in general agreement with corresponding findings in clinical trials for NASH. The present data therefore further supports the clinical translatability and utility of DIO-NASH and ob/ob-NASH mouse models of NASH for probing the therapeutic efficacy of compounds in preclinical drug development for NASH. | Kirstine S Tolbol Maria NB Kristiansen Henrik H Hansen Sanne S Veidal Kristoffer TG Rigbolt Matthew P Gillum Jacob Jelsing Niels Vrang Michael Feigh | 2018 | World Journal of Gastroenterology2018，24，2： | 5 |
| 5 | Diagnostic yield and clinical outcomes after capsule endoscopy in 100 consecutive patients with obscure gastrointestinal bleeding显示文摘 | Emilio Estévez Benito González-Conde José Luis Vázquez-Iglesias Maria de los Angeles Vázquez-Millán Sonia Pértega Pedro A. Alonso Joan Clofent Eva Santos José Luis Ulla Eloy Sánchez | 2006 | European Journal of Gastroenterology & Hepatology2006，，8： | 3 |
| 6 | Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients显示文摘 | Manuel Romero-Gómez Maria Del Mar Viloria Raúl J. Andrade Javier Salmerón Moisés Diago Conrado M. Fernández-Rodríguez Raquel Corpas Marina Cruz Lourdes Grande Luis Vázquez Paloma Mu?oz-de-Rueda Pilar López-Serrano Ana Gila María L. Gutiérrez Celia Pérez A | 2005 | Gastroenterology2005，，3： | 2 |
| 7 | Porcine circovirus type 2 (PCV2) Cap and Rep proteins are involved in the development of cell-mediated immunity upon PCV2 infection显示文摘 | Maria Fort Marina Sibila Miquel Nofrarías Eva Pérez-Martín Alex Olvera Enric Mateu Joaquim Segalés | 2010 | Veterinary Immunology and Immunopathology2010，，3： | 2 |
| 8 | N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized,placebo-controlled pilot study显示文摘AIM: To evaluate the effectiveness and safety of oral N-acetyl-L-cysteine (NAC) co-administration with mesalamine in ulcerative colitis (UC) patients. METHODS: Thirty seven patients with mild to moderate UC were randomized to receive a four-wk course of oral mesalamine (2.4 g/d) plus N-acetyl-L-cysteine (0.8 g/d) (group A) or mesalamine plus placebo (group B). Patients were monitored using the Modified Truelove-Witts Severity Index (MTWSI). The primary endpoint was clinical remission (MTWSI ≤ 2) at 4 wk. Secondary endpoints were clinical response (defined as a reduction from baseline in the MTWSI of ≥ 2 points) and drug safety. The serum TNF-α, interleukin-6, interleukin-8 and MCP-1 were evaluated at baseline and at 4 wk of treatment. RESULTS: Analysis per-protocol criteria showed clinical remission rates of 63% and 50% after 4 wk treatment with mesalamine plus N-acetyl-L-cysteine (group A) and mesalamine plus placebo (group B) respectively (OR = 1.71; 95% CI: 0.46 to 6.36; P = 0.19; NNT = 7.7). Analysis of variance (ANOVA) of data indicated a significant reduction of MTWSI in group A (P = 0.046) with respect to basal condition without significant changes in the group B (P = 0.735) during treatment. Clinical responses were 66% (group A) vs 44% (group B) after 4 wk of treatment (OR = 2.5; 95% CI: 0.64 to 9.65; P = 0.11; NNT = 4.5). Clinical improvement in group A correlated with a decrease of IL-8 and MCP-1. Rates of adverse events did not differ significantly between both groups. CONCLUSION: In group A (oral NAC combined with mesalamine) contrarily to group B (mesalamine alone), the clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8. NAC addition not produced any side effects. | Luis G Guijarro Jose Mate Javier P Gisbert Jose Luis Perez-Calle Ignacio Marín-Jimenez Encarna Arriaza Tomás Olleros Mario Delgado Maria S Castillejo David Prieto-Merino Venancio Gonzalez Lara Amado Salvador Pea | 2008 | World Journal of Gastroenterology2008，14，18： | 2 |
| 9 | On rough set logics based on similarity re- lations显示文摘 | Polkowski L Maria S P | 2005 | Fundamenta Informaticae2005，64，14： | 1 |
| 10 | VDR TaqI is associated with obesity in the Greek population显示文摘 | Yiannis V Theologia S Maria P | 2013 | Gene2013，，513： | 1 |
| 11 | Phthalates determination in pharmaceutical formulae used in parenteral nutrition by LC-ES-MS: Importance in public health 显示文摘 | Cristina P F Maria C B A Antia S D | 2010 | Analytical and Bioanalytieal Chemistry2010，397，2： | 1 |
| 12 | Germination of four species of the genus Mimosa (Leguminosae) in a semi-arid zone of Central Mexico 显示文摘 | MARIA S O LETICOA P L G ROSAURA G EDMUNDO G M | 2003 | Journal of Arid Environments2003，55，： | 1 |
| 13 | Phenols removal from apple juice by laccase immobilized on Cu^2+- chelate regeneable carrier 显示文摘 | Piera P Giovanni D S Maria S | 1997 | Biotechnology Techniques1997，11，7： | 1 |
| 14 | Addition effect of barium and strontium titanate on the reflectivity of ferri and ferromagnetic composites显示文摘 | Magali S P Maria L G Aristoteles S | 2002 | Microwave and Optical Technology Letters2002，32，5： | 1 |
| 15 | Long-term cyclability of nanostructured LiFePO4显示文摘 | PIER P P MARIA C SILVERA S | 2003 | Electrochimica Acta2003，48，： | 1 |
| 16 | Development of an enhanced bovine viral diarrhea virus subunit vaccine based on E2 glyco- protein fused to a single chain antibody which targets to antigen- presenting cells显示文摘 | Andrea Pecora Darfo A Malacara Maria S P(:rez Aguir- reburualde et al | 2015 | Revista Argentina de mi- crobiologia2015，，： | 1 |
| 17 | Characterization of a bacteriocin-like substance produced by a vaginal lactobacillus salivarius strain显示文摘 | Virginia S O Aida A P Maria E N | 1999 | Appl Environ Microbiol1999，65，5： | 1 |
| 18 | Simple Accurate Expressions for Planar Spiral Inductances显示文摘 | Sunderarajan S M Maria M H Stephen P B | 1999 | IEEE Journal of Soild-state Circuits1999，34，10： | 1 |
| 19 | Silica-immobilized piperazine:A sustainable organocatalyst for aldo/and knoevenage] reactions显示文摘 | SHANMUGANATHAN S GREINER L DE MARIA P D | 2010 | Tetrahedron Letters2010，51，50： | 1 |
| 20 | Solid-phase mieroex trac- tion and gas chromatography olfactometry analysis of succes- sively diluted samples: A new approach of the aroma extract di- lution analysis applied to the char acterization of wine aroma 显示文摘 | Maria P M Montserrat M Cristina S | 2003 | J Agric Food Chem2003，51，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员